% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mller:284032,
      author       = {Müller, Daniel J and Freitag, Christine M and Heilbronner,
                      Urs and Nöthen, Markus M and Perneczky, Robert and
                      Rietschel, Marcella and Schulte, Eva C and Deckert, Jürgen},
      collaboration = {Referat Genetische, molekulare und zelluläre
                      Neurowissenschaften der DGPPN},
      title        = {{G}enetisch informierte {T}herapie in der {P}sychiatrie:
                      neue {D}ynamik durch {APOE} und {A}ntikörpertherapie der
                      {A}lzheimer-{K}rankheit | {G}enetically informed treatment
                      in psychiatry: new dynamics through {APOE} and antibody
                      treatment of {A}lzheimer's disease},
      journal      = {Der Nervenarzt},
      volume       = {97},
      number       = {1},
      issn         = {0028-2804},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DZNE-2026-00075},
      pages        = {82 - 85},
      year         = {2026},
      abstract     = {The European Medicines Agency has recommended testing for
                      the ApoE-genotype prior to treatment of Alzheimer's disease
                      with Lecanemab. The drug approval is limited to patients who
                      are not homozygous for the ApoE epsilon 4 allele. This is to
                      reduce the risk of undesired adverse effects in the patients
                      treated with Lecanemab. With this recommendation for the
                      first time a psychiatric therapy will be genetically
                      informed.},
      subtyp        = {Review Article},
      keywords     = {Alzheimer Disease: genetics / Alzheimer Disease: drug
                      therapy / Alzheimer Disease: diagnosis / Humans /
                      Antibodies, Monoclonal, Humanized: therapeutic use /
                      Antibodies, Monoclonal, Humanized: adverse effects / Genetic
                      Testing: methods / Genetic Predisposition to Disease:
                      genetics / Apolipoproteins E: genetics / ApoE-genotype
                      (Other) / Adverse effects (Other) / Alzheimer disease
                      (Other) / Lecanemab (Other) / Medication safety (Other) /
                      Antibodies, Monoclonal, Humanized (NLM Chemicals) /
                      Apolipoproteins E (NLM Chemicals)},
      cin          = {AG Dichgans},
      ddc          = {610},
      cid          = {I:(DE-2719)5000022},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40548968},
      doi          = {10.1007/s00115-025-01839-1},
      url          = {https://pub.dzne.de/record/284032},
}